In addition, ERO1A, PKP2, and MERTK have been proved to promote the progress and drug resistance of NSCLC by enhancing the activation of tumor and PI3K, EGFR, and other signal pathways [33–35]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.